Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Xarelto Bleeding Lawsuits Consolidated Pennsylvania State Court, Reports Wright & Schulte LLC
  • USA - English


News provided by

Wright & Schulte LLC

Jan 28, 2015, 14:00 ET

Share this article

Share toX

Share this article

Share toX

Xarelto Bleeding Lawsuits Filed In Federal And State Courts Allege The Prescription Blood Thinner Causes Uncontrollable Or Fatal Bleeding Due To The Lack Of An Antidote
Xarelto Bleeding Lawsuits Filed In Federal And State Courts Allege The Prescription Blood Thinner Causes Uncontrollable Or Fatal Bleeding Due To The Lack Of An Antidote
Youtube
Youtube

If you believe you have suffered internal bleeding due to Xarelto contact the attorneys at Wright & Schulte LLC For a Free legal consult buy calling 1-800-399-0795 or visit www.yourlegalhelp.com

Post this

Columbus, OH (PRWEB) January 28, 2015 -- More than a month after federally filed Xarelto bleeding lawsuits were centralized in the U.S. District Court, District of Louisiana, Wright & Schulte LLC notes that all Xarelto lawsuits filed in Pennsylvania have been consolidated in the Philadelphia Court of Common Pleas. The firm further notes, court records indicate that Administrative Judge Kevin Dougherty, of the Philadelphia Court of Common Pleas, created a mass tort litigation program for the 75 Xarelto bleeding lawsuits filed against Bayer Healthcare Pharmaceuticals, the maker of the blood thinner medication, and Johnson & Johnson’s Janssen Pharmaceuticals unit, which markets the blood thinner Xarelto. In his order issued on January 20, Judge Dougherty said he was granting a plaintiff’s petition which asked the court to transfer the Xarelto complaints to the court’s Complex Litigation Center for coordinated pretrial proceedings. The Xarelto lawsuits allege that patients who used the prescription blood thinner experienced uncontrollable or fatal bleeding side-effects due to the lack of an antidote to reverse the effects of the anticoagulant medication. (In Re: Xarelto Litigation, Case Number 150102349)

Wright & Schulte LLC continues to investigate purported Xarelto bleeding side-effects experienced by men and women across the country. The firm offers free legal consultations to those who believe they have experienced uncontrollable bleeding, hemorrhaging and other side-effects as a result of using Xarelto and other prescription blood thinners. To speak with one of the firm’s experienced attorneys please call 1-800-399-0795 or visit yourlegalhelp.com for more information on this and other prescription drug lawsuits. "With Xarelto lawsuits filed throughout the state of Pennsylvania and the country, it allows for a more cohesive litigation process"

Xarelto (rivaroxaban) is an oral anticoagulant approved by the U.S. Food and Drug Administration (FDA) to treat deep vein thrombosis (blood clots in the leg) and pulmonary embolism (blood clots in the lung) and to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). Xarelto is considered a new generation blood thinner compared to warfarin (Coumadin, Jantoven), a blood thinner that has been on the market since its FDA approval in 1954. The FDA notes that the new generation of blood thinner medications, which includes Xarelto, Eliquis and Pradaxa, do not have antidotes to stop severe bleeding in patients who use the drugs. Warfarin uses vitamin K as a reversal agent should serious bleeding occur in patients who take the prescription blood thinner.
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012]
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

The firm further comments that just as a petition was filed to consolidate Xarelto lawsuit complaints in Philadelphia, court records indicate that a plaintiff’s request was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to centralize all Xarelto complaints filed in federal courts across the country. Plaintiffs involved in Xarelto lawsuits filed a motion with the judicial panel which said in part that there were 1,080 Xarelto-related serious events reported to the FDA in the year leading up to June 30, 2012, including 65 deaths. The motion went on to say that there were over 2,000 new reports filed with the FDA by the end of 2012. After hearing oral arguments on the consolidation request, the JPML in December granted the request and transferred 21 Xarelto complaints to the U.S. District Court, Eastern District of Louisiana. The judicial panel explained that consolidating the Xarelto lawsuits will help to prevent inconsistent rulings and eliminate duplicate discovery during the pretrial process. As of January 15, there are 86 Xarelto lawsuits pending in the Xarelto multidistrict litigation which is being supervised by U.S. District Judge Eldon E. Fallon. The first status conference for Xarelto MDL 2592 is scheduled for January 29. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592)

According to the petition requesting Xarelto consolidation in the Pennsylvania state court, Wright & Schulte notes all of the pending Xarelto complaints have similar legal and factual issues and allege that Bayer and Janssen Pharmaceuticals failed to warn doctors that Xarelto does not have reversing agents which leaves trauma professionals in emergency rooms without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding due to taking Xarelto. (In Re: Xarelto Litigation, Case Number 150102349) The Pennsylvania Record reported that Janssen and Bayer opposed the consolidation in the Philadelphia Court of Common Pleas. According to the report, Janssen issued a statement saying that the company will defend itself against the Xarelto claims. The company went on to say that all blood thinners have a bleeding risk and Xarelto’s prescribing information “has always warned of these risks.”
[pennrecord.com/news/15536-philadelphia-court-establishes-xarelto-mass-tort-docket, January 22, 2015]

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Xarelto bleeding lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.